Previous close | 0.3500 |
Open | 0.2500 |
Bid | 0.0700 |
Ask | 0.1000 |
Strike | 80.00 |
Expiry date | 2024-05-31 |
Day's range | 0.1100 - 0.3600 |
Contract range | N/A |
Volume | |
Open interest | 363 |
Medtronic ( NYSE:MDT ) Full Year 2024 Results Key Financial Results Revenue: US$32.4b (up 3.6% from FY 2023). Net...
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Medtronic Plc (NYSE:MDT) reported fourth-quarter 2024 sales of $8.59 billion, beating the consensus of $8.44 billion. Revenue increased 0.5%, as reported, and 5.4% organic. The company’s organic revenue results reflect broad-based growth across the company, with mid-single-digit or higher organic revenue growth in all four segments. The medical device maker reported adjusted EPS of $1.46, beating the consensus of $1.45. Related: Medtronic’s Latest Generation Of Transcatheter Aortic Valve Replace